Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Mogamulizumab (Primary) ; Durvalumab; Tremelimumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 22 May 2017 Planned number of patients changed from 108 to 81.
- 22 May 2017 Planned End Date changed from 1 Nov 2017 to 1 May 2018.